Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accumulated Expenses (2016 - 2025)

Corcept Therapeutics' Accumulated Expenses history spans 10 years, with the latest figure at $88.9 million for Q1 2025.

  • For Q1 2025, Accumulated Expenses rose 258.01% year-over-year to $88.9 million; the TTM value through Mar 2025 reached $88.9 million, up 258.01%, while the annual FY2024 figure was $90.7 million, 547.86% up from the prior year.
  • Accumulated Expenses for Q1 2025 was $88.9 million at Corcept Therapeutics, down from $90.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $90.7 million in Q4 2024 and bottomed at $14.0 million in Q2 2023.
  • The 5-year median for Accumulated Expenses is $26.2 million (2021), against an average of $39.0 million.
  • The largest annual shift saw Accumulated Expenses plummeted 54.54% in 2023 before it skyrocketed 547.86% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $27.7 million in 2021, then increased by 11.33% to $30.8 million in 2022, then tumbled by 54.54% to $14.0 million in 2023, then surged by 547.86% to $90.7 million in 2024, then dropped by 2.01% to $88.9 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Accumulated Expenses are $88.9 million (Q1 2025), $90.7 million (Q4 2024), and $24.8 million (Q1 2024).